III期-话题@MedSci

#III期#

681篇内容 | 2795人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594627, encodeId=6baa159462e19, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, objectType=article, longId=177383, objectId=b6d81e73834c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d81e73834c, replyNumber=0, likeNumber=51, createdTime=2019-08-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d81e73834c, moduleTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6d81e73834c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594626, encodeId=9bfd1594626f0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, objectType=article, longId=177339, objectId=a5a91e73396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5a91e73396a, replyNumber=0, likeNumber=73, createdTime=2019-08-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5a91e73396a, moduleTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5a91e73396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594625, encodeId=c509159462535, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组, objectType=article, longId=177305, objectId=15131e730596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15131e730596, replyNumber=0, likeNumber=52, createdTime=2019-08-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15131e730596, moduleTitle=MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15131e730596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594624, encodeId=182b159462412, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=赛诺菲白细胞介素4/13单抗Dupixent在严重特应性皮炎儿童患者的III期试验成功, objectType=article, longId=177128, objectId=d21f1e7128a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d21f1e7128a2, replyNumber=0, likeNumber=75, createdTime=2019-08-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d21f1e7128a2, moduleTitle=赛诺菲白细胞介素4/13单抗Dupixent在严重特应性皮炎儿童患者的III期试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d21f1e7128a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594623, encodeId=3501159462397, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, objectType=article, longId=177126, objectId=a2121e71269e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2121e71269e, replyNumber=0, likeNumber=0, createdTime=2019-08-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2121e71269e, moduleTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2121e71269e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594622, encodeId=74e11594622c8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Rivipansel治疗镰状细胞病的III期试验：未达到主要终点, objectType=article, longId=176941, objectId=47371e6941f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47371e6941f2, replyNumber=0, likeNumber=68, createdTime=2019-08-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47371e6941f2, moduleTitle=Rivipansel治疗镰状细胞病的III期试验：未达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47371e6941f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594621, encodeId=96011594621ea, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Saroglitazar Magnesium治疗2型糖尿病的III期试验取得积极结果, objectType=article, longId=176832, objectId=b5881e683297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5881e683297, replyNumber=0, likeNumber=75, createdTime=2019-08-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5881e683297, moduleTitle=Saroglitazar Magnesium治疗2型糖尿病的III期试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5881e683297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594620, encodeId=37c7159462071, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验, objectType=article, longId=176830, objectId=36111e683054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36111e683054, replyNumber=0, likeNumber=55, createdTime=2019-08-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36111e683054, moduleTitle=不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36111e683054)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594619, encodeId=15b2159461962, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, objectType=article, longId=176219, objectId=d8491e621960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8491e621960, replyNumber=0, likeNumber=51, createdTime=2019-07-28, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8491e621960, moduleTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8491e621960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594618, encodeId=98ea159461884, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光, objectType=article, longId=176064, objectId=15841e606424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15841e606424, replyNumber=0, likeNumber=60, createdTime=2019-07-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15841e606424, moduleTitle=PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15841e606424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594617, encodeId=b52f159461ebc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=樊旼教授：PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光, objectType=article, longId=176018, objectId=5b4a1e6018c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b4a1e6018c7, replyNumber=0, likeNumber=55, createdTime=2019-07-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b4a1e6018c7, moduleTitle=樊旼教授：PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b4a1e6018c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594616, encodeId=12a41594616c1, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=细菌性肺炎治疗遭遇挫折：已停止Murepavadin静脉注射制剂的III期PRISM研究, objectType=article, longId=175764, objectId=783b1e5764e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=783b1e5764e6, replyNumber=0, likeNumber=62, createdTime=2019-07-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=783b1e5764e6, moduleTitle=细菌性肺炎治疗遭遇挫折：已停止Murepavadin静脉注射制剂的III期PRISM研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=783b1e5764e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594615, encodeId=13e615946157d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性, objectType=article, longId=175129, objectId=21e61e5129ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21e61e5129ae, replyNumber=0, likeNumber=18, createdTime=2019-07-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21e61e5129ae, moduleTitle=2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e61e5129ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594614, encodeId=76d1159461453, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=石安辉教授：PACIFIC研究开创III期NSCLC免疫治疗新篇, objectType=article, longId=175125, objectId=ace01e5125f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ace01e5125f6, replyNumber=0, likeNumber=57, createdTime=2019-07-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ace01e5125f6, moduleTitle=石安辉教授：PACIFIC研究开创III期NSCLC免疫治疗新篇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ace01e5125f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594613, encodeId=d2c61594613c9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功, objectType=article, longId=175120, objectId=15c11e51207f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15c11e51207f, replyNumber=0, likeNumber=66, createdTime=2019-07-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15c11e51207f, moduleTitle=2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15c11e51207f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594612, encodeId=0697159461274, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, objectType=article, longId=174669, objectId=3b101e46693f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b101e46693f, replyNumber=0, likeNumber=0, createdTime=2019-07-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b101e46693f, moduleTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b101e46693f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594611, encodeId=7c69159461151, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=枸橼酸西地那非治疗新生儿持续性肺动脉高压的III期试验结果, objectType=article, longId=174500, objectId=3cc31e45003d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cc31e45003d, replyNumber=0, likeNumber=68, createdTime=2019-07-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cc31e45003d, moduleTitle=枸橼酸西地那非治疗新生儿持续性肺动脉高压的III期试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cc31e45003d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594610, encodeId=b9191594610a9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, objectType=article, longId=174364, objectId=c1da1e436402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e436402, replyNumber=0, likeNumber=19, createdTime=2019-06-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e436402, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e436402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594609, encodeId=6bf21594609b1, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=历史照进现实 ——III期非小细胞肺癌免疫治疗的突破, objectType=article, longId=168855, objectId=9c471688550f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c471688550f, replyNumber=0, likeNumber=65, createdTime=2019-06-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c471688550f, moduleTitle=历史照进现实 ——III期非小细胞肺癌免疫治疗的突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c471688550f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594608, encodeId=b5081594608a9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=PACIFIC方案已是III期不可切除非小细胞肺癌的标准疗法, objectType=article, longId=168273, objectId=368a1682e321, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=368a1682e321, replyNumber=0, likeNumber=89, createdTime=2019-06-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=368a1682e321, moduleTitle=PACIFIC方案已是III期不可切除非小细胞肺癌的标准疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=368a1682e321)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率

2019-08-12

智智灵药 (审核中...)

前往app查看评论内容

#III期#

阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功

2019-08-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组

2019-08-10

智智灵药 (审核中...)

前往app查看评论内容

#III期#

赛诺菲白细胞介素4/13单抗Dupixent在严重特应性皮炎儿童患者的III期试验成功

2019-08-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人

2019-08-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Rivipansel治疗镰状细胞病的III期试验：未达到主要终点

2019-08-07

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Saroglitazar Magnesium治疗2型糖尿病的III期试验取得积极结果

2019-08-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验

2019-08-05

docwu2019 (审核中...)

前往app查看评论内容

#III期#

Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点

2019-07-28

智智灵药 (审核中...)

前往app查看评论内容

#III期#

PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光

2019-07-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

樊旼教授：PACIFIC研究“海啸”袭来，III期肺癌迎接治愈曙光

2019-07-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

细菌性肺炎治疗遭遇挫折：已停止Murepavadin静脉注射制剂的III期PRISM研究

2019-07-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性

2019-07-12

智智灵药 (审核中...)

前往app查看评论内容

#III期#

石安辉教授：PACIFIC研究开创III期NSCLC免疫治疗新篇

2019-07-12

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功

2019-07-12

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效

2019-07-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

枸橼酸西地那非治疗新生儿持续性肺动脉高压的III期试验结果

2019-07-01

智智灵药 (审核中...)

前往app查看评论内容

#III期#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点

2019-06-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

历史照进现实 ——III期非小细胞肺癌免疫治疗的突破

2019-06-22

智智灵药 (审核中...)

前往app查看评论内容

#III期#

PACIFIC方案已是III期不可切除非小细胞肺癌的标准疗法

2019-06-14

科室
- - 订阅+
  - 更多科室
工具
服务